Invasive Pulmonary Aspergillosis in Patients with Chronic Obstructive Pulmonary Disease: An Emerging Fungal Disease
- 269 Downloads
Invasive pulmonary aspergillosis (IPA) is a necrotizing pneumonia caused by airborne opportunistic fungi of Aspergillus species. Patients with advanced-stage chronic obstructive pulmonary disease (COPD) have emerged to be at risk for IPA as a result of the overall improvement of long-term management of the disease. IPA is among the most severe infectious event that may occur during the course of COPD resulting from profound immune impairment and associated with poor outcome. Many aspects of the development of IPA in COPD patients differ from hematologic patients, explaining various patterns of IPA in an expanded population of immunocompromised patients. Therefore, it is legitimate to focus on the literature-based data available regarding the factors involved in the development of IPA in this setting as well as the use and interpretation of diagnosis criteria, and the treatment options.
KeywordsInvasive pulmonary aspergillosis Aspergillus Chronic obstructive pulmonary disease Corticosteroids
No potential conflict of interest relevant to this article was reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Ader F, Bienvenu AL, Rammaert B, Nseir S: Management of invasive aspergillosis in patients with COPD: rational use of voriconazole. Int J COPD 2009, 4:279–287.Google Scholar
- 13.•• Bulpa P, Dive A, and Sibille Y: Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007, 30:782–800. This study was the first to propose specific definitions of IPA in COPD patients. The “Bulpa criteria” are currently used to estimate the probability of IPA in COPD patients.CrossRefPubMedGoogle Scholar
- 16.•• Guinea J, Torres-Narbona M, Gijon P, et al.: Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2009 (Epub ahead of print). This study presents and analyzes the largest retrospective series of COPD patients with positive Aspergillus specimens in LRT at admission who subsequently develop IPA.Google Scholar
- 23.De Pauw B, Walsh TJ, Donnelly JP, et al.: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813–1821.CrossRefPubMedGoogle Scholar
- 39.• Seidler MJ, Salvenmoser S, Müller FMC: Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob Agents Chemother 2008, 52:4130–4136. This is the first report of biofilm production by A. fumigatus on bronchial epithelial cells.CrossRefPubMedGoogle Scholar
- 48.Sanguinetti M, Posteraro B, Pagano L, et al.: Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2003, 41:3922–3925.CrossRefPubMedGoogle Scholar
- 52.• Meersseman W, Lagrou K, Maertens J, et al.: Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008, 177:27–34. This clinical study investigated GM detection in BAL fluid of ICU patients and underscored the usefulness of GM detection in establishing or excluding the diagnosis of IPA in the ICU.CrossRefPubMedGoogle Scholar